Meridian Medical Technologies
This article was originally published in The Gray Sheet
Firm recalls 47 lots of EpiPen and EpiPen Jr. auto-injectors because some of the devices "may not provide effective doses of medication to treat acute allergic emergencies (anaphylaxis)," the firm reports May 8. The Class I recall seeks to retrieve auto-injectors distributed in the U.S., Germany, Israel, Denmark, Canada, Turkey, Australia, Greece and South Africa. No patients have been affected by the problem, which "arose in the process of advancing our automated production capabilities," Meridian states
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.